{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:54:04Z","timestamp":1792814044893,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Objective<\/jats:title>\n                  <jats:p>Apparent mineralocorticoid excess (AME) syndrome is an ultra-rare autosomal-recessive tubulopathy, caused by mutations in HSD11B2, leading to excessive activation of the kidney mineralocorticoid receptor, and characterized by early-onset low-renin hypertension, hypokalemia, and risk of chronic kidney disease (CKD). To date, most reports included few patients, and none described patients from Israel. We aimed to describe AME patients from Israel and to review the relevant literature.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective cohort study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Clinical, laboratory, and molecular data from patients\u2019 records were collected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Five patients presented at early childhood with normal estimated glomerular filtration rate (eGFR), while 2 patients presented during late childhood with CKD. Molecular analysis revealed 2 novel homozygous mutations in HSD11B2. All patients presented with severe hypertension and hypokalemia. While all patients developed nephrocalcinosis, only 1 showed hypercalciuria. All individuals were managed with potassium supplements, mineralocorticoid receptor antagonists, and various antihypertensive medications. One patient survived cardiac arrest secondary to severe hyperkalemia. At last follow-up, those 5 patients who presented early exhibited normal eGFR and near-normal blood pressure, but 2 have hypertension complications. The 2 patients who presented with CKD progressed to end-stage kidney disease (ESKD) necessitating dialysis and kidney transplantation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this 11-year follow-up report of 2 Israeli families with AME, patients who presented early maintained long-term normal kidney function, while those who presented late progressed to ESKD. Nevertheless, despite early diagnosis and management, AME is commonly associated with serious complications of the disease or its treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvae049","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T18:30:14Z","timestamp":1713897014000},"page":"347-353","source":"Crossref","is-referenced-by-count":4,"title":["Apparent mineralocorticoid excess in Israel: a case series and literature review"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5440-2414","authenticated-orcid":false,"given":"Asaf","family":"Lebel","sequence":"first","affiliation":[{"name":"Pediatric Nephrology Unit, HaEmek Medical Center , Afula 1834111 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Ben Shalom","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Unit, Shaare Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem , Jerusalem 9103102 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozan","family":"Mokatern","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Unit, HaEmek Medical Center , Afula 1834111 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Halevy","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology Unit, HaEmek Medical Center , Afula 1834111 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoav","family":"Zehavi","sequence":"additional","affiliation":[{"name":"Pediatric Department B, HaEmek Medical Center , Afula 1834111 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Magen","sequence":"additional","affiliation":[{"name":"Technion Faculty of Medicine, Pediatric Nephrology Institute, Ruth Children\u2019s Hospital, Rambam Health Care Campus , Haifa 3109601 , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"issue":"5","key":"2024053109213971100_lvae049-B1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1210\/jcem-44-5-924","article-title":"Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension","volume":"44","author":"New","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024053109213971100_lvae049-B2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1210\/jcem-49-5-757","article-title":"A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol","volume":"49","author":"Ulick","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024053109213971100_lvae049-B3","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1016\/0303-7207(94)90176-7","article-title":"Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme","volume":"105","author":"Albiston","year":"1994","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"2024053109213971100_lvae049-B4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000134089","article-title":"Localization of the gene for human 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) to chromosome band 16q22","volume":"71","author":"Krozowski","year":"1995","journal-title":"Cytogenet Cell Genet"},{"issue":"1","key":"2024053109213971100_lvae049-B5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/geno.1995.1231","article-title":"Gene structure and chromosomal localization of the human HSD11 K gene encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid dehydrogenase","volume":"29","author":"Agarwal","year":"1995","journal-title":"Genomics"},{"issue":"3","key":"2024053109213971100_lvae049-B6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1152\/physrev.00020.2012","article-title":"11\u03b2-Hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action","volume":"93","author":"Chapman","year":"2013","journal-title":"Physiol Rev"},{"issue":"3","key":"2024053109213971100_lvae049-B7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/713609355","article-title":"Pseudohyperaldosteronism: pathogenetic mechanisms","volume":"40","author":"Armanini","year":"2003","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"1","key":"2024053109213971100_lvae049-B8","first-page":"135","article-title":"11 beta-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess","volume":"18","author":"White","year":"1997","journal-title":"Endocr Rev"},{"issue":"22","key":"2024053109213971100_lvae049-B9","doi-asserted-by":"crossref","first-page":"12790","DOI":"10.1073\/pnas.96.22.12790","article-title":"Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess","volume":"96","author":"New","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2024053109213971100_lvae049-B10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2024053109213971100_lvae049-B11","first-page":"323","article-title":"Report of the second task force on blood pressure control in children","volume":"36","author":"Zahka","year":"1987","journal-title":"Md Med J"},{"issue":"3","key":"2024053109213971100_lvae049-B12","doi-asserted-by":"crossref","first-page":"e20171904","DOI":"10.1542\/peds.2017-1904","article-title":"Clinical practice guideline for screening and management of high blood pressure in children and adolescents","volume":"140","author":"Flynn","year":"2017","journal-title":"Pediatrics"},{"issue":"1","key":"2024053109213971100_lvae049-B13","first-page":"622","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Andrassy","year":"2012","journal-title":"Kidney Int"},{"issue":"24","key":"2024053109213971100_lvae049-B14","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJM199812103392414","article-title":"Cure of apparent mineralocorticoid excess by kidney transplantation","volume":"339","author":"Palermo","year":"1998","journal-title":"N Engl J Med"},{"issue":"1","key":"2024053109213971100_lvae049-B15","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12967-022-03698-9","article-title":"Apparent mineralocorticoid excess: comprehensive overview of molecular genetics","volume":"20","author":"Lu","year":"2022","journal-title":"J Transl Med"},{"issue":"52","key":"2024053109213971100_lvae049-B16","doi-asserted-by":"crossref","first-page":"E11248","DOI":"10.1073\/pnas.1716621115","article-title":"Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11\u03b2-hydroxysteroid dehydrogenase type 2 deficiency","volume":"114","author":"Yau","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024053109213971100_lvae049-B17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/nyas.13162","article-title":"A novel mutation in HSD11B2 causes apparent mineralocorticoid excess in an Omani kindred","volume":"1376","author":"Yau","year":"2016","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"2024053109213971100_lvae049-B18","first-page":"2244","article-title":"Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess","volume":"83","author":"Dave-Sharma","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024053109213971100_lvae049-B19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00467-019-04329-0","article-title":"A rare cause of hypertension in childhood: answers","volume":"35","author":"Kucuk","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"2024053109213971100_lvae049-B20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1365-2265.1996.677500.x","article-title":"Apparent mineralocorticoid excess due to 11 beta-hydroxysteroid dehydrogenase deficiency: a possible cause of intrauterine growth retardation","volume":"44","author":"Kitanaka","year":"1996","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2024053109213971100_lvae049-B21","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1681\/ASN.2006060570","article-title":"Apparent mineralocorticoid excess: report of six new cases and extensive personal experience","volume":"17","author":"Morineau","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2024053109213971100_lvae049-B22","doi-asserted-by":"crossref","first-page":"F494","DOI":"10.1152\/ajprenal.00165.2012","article-title":"A urine-concentrating defect in 11\u03b2-hydroxysteroid dehydrogenase type 2 null mice","volume":"303","author":"Evans","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1-2","key":"2024053109213971100_lvae049-B23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s004670000377","article-title":"Nephrocalcinosis and renal cysts associated with apparent mineralocorticoid excess syndrome","volume":"15","author":"Moudgil","year":"2000","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"2024053109213971100_lvae049-B24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00467-021-05049-0","article-title":"Molecular mechanisms altering tubular calcium reabsorption","volume":"37","author":"Downie","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2024053109213971100_lvae049-B25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/ijms21010369","article-title":"Nephrocalcinosis: a review of monogenic causes and insights they provide into this heterogeneous condition","volume":"21","author":"Dickson","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2024053109213971100_lvae049-B26","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1097\/01.ASN.0000028640.78526.0F","article-title":"Modulation of renal calcium handling by 11 beta-hydroxysteroid dehydrogenase type 2","volume":"13","author":"Ferrari","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2024053109213971100_lvae049-B27","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00467-021-05246-x","article-title":"Monogenic forms of low-renin hypertension: clinical and molecular insights","volume":"37","author":"Khandelwal","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"2024053109213971100_lvae049-B28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12020-020-02460-9","article-title":"Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia","volume":"70","author":"Fan","year":"2020","journal-title":"Endocrine"},{"key":"2024053109213971100_lvae049-B29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jsbmb.2016.02.014","article-title":"Apparent mineralocorticoid excess and the long term treatment of genetic hypertension","volume":"165","author":"Razzaghy-Azar","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"2024053109213971100_lvae049-B30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s12020-020-02488-x","article-title":"Apparent mineralocorticoid excess: research as an art form","volume":"70","author":"Funder","year":"2020","journal-title":"Endocrine"},{"issue":"3","key":"2024053109213971100_lvae049-B31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/HJH.0000000000001201","article-title":"Apparent mineralocorticoid excess caused by a novel mutation in 11\u03b2-hydroxysteroid dehydrogenase type 2 gene","volume":"35","author":"Wang","year":"2017","journal-title":"J Hypertens"},{"issue":"2","key":"2024053109213971100_lvae049-B32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1086\/301955","article-title":"Molecular basis for hypertension in the \u201ctype II variant\u201d of apparent mineralocorticoid excess","volume":"63","author":"Li","year":"1998","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2024053109213971100_lvae049-B33","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1210\/jc.2018-01197","article-title":"Clinical, biochemical, and genetic characteristics of \u201cnonclassic\u201d apparent mineralocorticoid excess syndrome","volume":"104","author":"Tapia-Castillo","year":"2019","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvae049\/57312370\/lvae049.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/5\/347\/57806897\/lvae049.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/5\/347\/57806897\/lvae049.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T19:55:27Z","timestamp":1717185327000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/190\/5\/347\/7656906"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvae049","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,4,23]]}}}